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ABSTRACT 
Background: Mutations of isocitrate dehydrogenase 1 and 2 are novel common genetic 
alterations identified in acute myeloid leukemia. 
Aims: To investigate the frequency, clinical associations and prognostic effect of isocitrate 
dehydrogenase 1 and 2 mutations together, followed by a detailed investigation of particular 
mutations. 
Methods: A consecutive cohort of 376 patients diagnosed with acute myeloid leukemia were 
enrolled to compare clinical characteristics. Prognostic impact was analyzed for 314 patients 
younger than 60 years treated with curative intention. Isocitrate dehydrogenase 1 and 2 
mutations were screened using allele-specific PCR and high resolution melting, followed by a 
confirmatory sequencing. 
Results: Isocitrate dehydrogenase (IDH) 1 and 2 mutations were mutually exclusive, detected 
in 8.5% and 7.5% of the cases respectively. Presence of mutations was associated with older 
age (p=0.001), higher platelet count (p=0.001), intermediate risk karyotype (p<0.0001), 
nucleophosmin1 mutation (p=0.022), and with lower mRNA expression level of ABCG2 gene 
(p=0.006), as compared to mutation negative cases. Remission, relapse rates and overall 
survival were not different in IDH-mutation positive patients. Interestingly, particular 
mutations differred in association with nucleophosmin1 mutation: co-occurrence was 
observed in 14.3% of R132C vs. 70% of R132H carriers (p=0.02); and in 47.4% of R140Q vs. 
0% R172K carriers (p=0.02) of IDH1 and IDH2 genes, respectively. R132H negatively 
influenced overall survival compared to isocitrate dehidrogenase 1 and 2 negative (p=0.02) or 
to R132C (p=0.019) patients. 
Conclusions: IDH mutations are frequent recurrent mutations in acute myeloid leukemia. 
Although a general common pathogenetic role is proposed, our results indicate that 
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differences in clinical characteristics and treatment outcome may exist among disctinct 
mutations of both genes. 
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INTRODUCTION 
Acute myeloid leukemia (AML) has a highly heterogeneous genetic background.(1) The 
number of known genetic alterations increases steadily and newly identified mutations may 
provide a deeper insight into the pathogenesis of AML.(2) Mutational profiling helps to 
improve risk stratification and to bring better founded therapeutic decisions.(3) IDH1 somatic 
mutation (R132C) was initially described in colon cancer.(4) Later, IDH1 mutations affecting 
codon R132 and IDH2 mutations affecting codon R172 were also discovered in gliomas.(5, 6) 
Overlapping arrays of mutations occur in around 15% of all AML cases.(7) 
Under normal circumstances, IDH enzymes catalyze the conversion of isocitrate to α–
ketoglutarate (αKG). The presence of IDH mutant enzymes results in aberrant production of 
2-hydroxyglutarate (2HG), the structural analogue and competitive inhibitor of αKG. The 
production of 2HG is a common neomorphic activity of all IDH1 and 2 mutations resulting in 
the block of αKG dependent enzymes such as tet methylcytosine dioxygenases 1 and 2 (TET1 
and 2), or histone demethylases causing aberrant DNA and histone methylation, altered gene 
expression profiles and consecutively impaired stem cell differentiation.(2, 8, 9) In line with 
the common pathogenic background, IDH1 and IDH2 mutation positive AML cases share 
several common clinical characteristics, including an older age of onset, higher platelet count, 
and association with intermediate cytogenetic risk.(10-23) However, distinctive differences 
between IDH1 and IDH2 mutations or even between particular IDH2 substitutions (R140 and 
R172) have recently been reported to affect morphology, or to associate with nucleophosmin 
1 (NPM1) mutation and treatment outcome.(14, 16)  
In this study, we analyzed the impact of IDH mutations on clinical characteristics (age, 
AML etiology, morphology, hematological laboratory parameters, karyotype, molecular 
genetic alteration at presentation) and prognostic outcome (remission, relapse rates, overall 
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and disease free survival). Following the combined analysis, we investigated the role of the 
particular IDH1 and IDH2 substitutions separately in a Hungarian cohort of AML patients. 
 
PATIENTS AND METHODS 
Patients 
Our cohort consisted of 376 consecutive AML patients [180 males/196 females; median 
age: 48.6 years (range: 16-93)]. The patients were diagnosed and treated at the Department of 
Hematology and Stem Cell Transplantation, St. Istvan and St. Laszlo Hospital (formerly 
National Medical Center) between 2001 and 2009. The minimal follow up was 12 months 
(maximum: 107 months). Clinical data were collected retrospectively. Complete remission, 
early death (less than 28 days after the start of therapy), resistant disease, disease-free survival 
(DFS) and overall survival (OS) were defined according to recommended criteria.(1) 
Immunophenotyping was performed by a panel of monoclonal antibodies (CD7, CD13, 
CD14, CD33, CD34, HLA-DR). Cytogenetic abnormalities, based on at least 20 cells in 
metaphase were described according to the International System for Human Cytogenetic 
Nomenclature (ISCN 2005). Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication 
(ITD) and nucleophosmin 1 (NPM1) mutations were analyzed by PCR followed by capillary 
gel electrophoresis. ABCG2 mRNA expression in the bone marrow at diagnosis was tested by 
real-time quantitative PCR by pre-developed TaqMan Gene Expression Assay 
(Hs01053790_m1, Life Technologies, Carslbad, USA) using LightCycler 480. ABL was used 
as a reference gene.(24) Patients signed informed consents in agreement with the Regional 
Ethics Committee approval. 
 
IDH1 and IDH2 mutation analysis 
IDH1 and IDH2 mutation analyses were performed on genomic DNA isolated from bone 
marrow samples at the time of diagnosis. Allele-specific PCR (AS-PCR) for IDH1 R132 
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codon mutations was adapted from Chou et al.(25) A similar single-tube, multiplex AS-PCR 
method was developed for the simultaneous detection of IDH2 R140 and R172 mutations. 
High resolution melting (HRM) analysis was performed using LightCycler 480 Real-Time 
PCR System. AS-PCR was used as a primary screening method in all AML patients, and 
HRM was performed in parallel in patients with normal karyotype and in patients with 
positive AS-PCR screen. Sequencing using Beckman Coulter CEQ 8000 Genetic Analyser 
was performed in cases of IDH1 codon 132 mutantion detected by AS-PCR and HRM to 
determine the exact amino acid substitution. 
 
Statistical analyses 
Continuous variables are presented as median and range. Mann-Whitney or Kruskal-Wallis 
tests were used to compare continuous variables in subgroups according to IDH1/2 mutations. 
Fischer’s exact test and χ2 test were performed to compare dichotomous variables. Log-rank 
test was used to compare DFS and OS between groups separated by IDH mutation status. A 
Cox proportional hazards model was computed for multivariate analysis of OS and DFS with 
the calculation of hazard ratio (HR) and 95% confidence interval (95%CI). The statistics was 
performed using Statistical Package for the Social Science [(SPSS) version 13.0]. 
 
RESULTS 
To characterize the frequencies of IDH1 and IDH2 mutations, we screened 376 AML 
patients by AS-PCR and HRM. 32 patients had a mutation in IDH1 (8.5%) and 28 patients in 
IDH2 (7.5%). IDH1 and IDH2 mutations were mutually exclusive. In IDH1, R132C (n=14, 
43.8%) was the most frequent alteration, in addition, R132H (n=10, 31.3%), R132G (n=5, 
15.6%), R132L (n=2, 6.2%) and R132S (n=1, 3.1%) were detected. In the IDH2 gene, twenty 
R140Q (71.4%) and eight R172K (28.6%) substitutions were identified. 
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Clinical features of IDH mutation positive AML patients 
First, we investigated IDH1 and IDH2 mutation positive patients combined (IDH1/2
mut
), 
which was followed by the analysis of IDH1
mut
 and IDH2
mut
 subtypes separately (analyses for 
the entire AML group are shown in Table 1). A further stratification was performed for the 
separate analysis of IDH1 R132C and R132H or IDH2 R140Q and R172K mutations 
(separated analyses for the entire AML group are shown in Table 2). We compared IDH 
mutation positive to IDH1/2 double negative patients (IDH1/2
neg
). 
In the entire AML group, IDH1/2 mutations together, as well as IDH1 and IDH2 separately 
including R132C and R140Q subtypes presented at older age (medians and ranges are listed) 
[IDH1
mut
: 54.5 (30-93 years); IDH2
mut
: 56.5 (31-77 years) compared to IDH1/2
neg
 :49.0 (16-
86 years); p=0.013 and p=0.009, respectively]. IDH mutations showed no associaton with sex, 
etiology of AML or white blood cell (WBC) count at diagnosis. Higher platelet count (PLT) 
was observed in IDH1/2
mut
, IDH1
mut
 and IDH2
mut
 as well as in R132C, R132H and R140Q 
mutants [IDH1
mut
: 75 (10-326 G/L); IDH2
mut
: 72 (5-215 G/L); vs. IDH1/2
neg
: 39 (5-684 G/L); 
p=0.039, p=0.005]. R172K was associated with a lower lactate dehydrogenase (LDH) level 
[R172K: 411 (217-1398 U/L) vs. IDH1/2
neg
: 734 (136-15418 U/L), p=0.043]. No difference 
could be observed in morphological distribution according to FAB. 
IDH1 and IDH2 mutation positive patients had intermediate risk karyotype more 
frequently [IDH1
mut
: 80.6%, IDH2
mut
: 81.5% vs. IDH1/2
neg
: 52.7%; p=0.004, p=0.004]. None 
of the IDH substitutions were preferentially associated with FLT3 ITD. IDH1/2 and IDH1 
positive patients had predominantly NPM1 mutation (IDH1
mut
: 42.0% vs. IDH1/2
neg
: 23.2%; 
p=0.029), while IDH2 was not associated with NPM1 mutations (33.3%, p=0.24). 
IDH1/2, IDH2 as well as R132C and R140Q mutants showed lower mRNA expression of 
ABCG2 gene at diagnosis (ABCG2 transcript/ABL transcript %) [IDH2
mut
: 0.51 (0.05-3.24%) 
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vs. IDH1/2
neg
: 1.35 (0.02-18.05%); p=0.012]. IDH1
mut
 also showed a tendency toward lower 
expression [0.52 (0.01-23.01%); p=0.062]. On the other hand, ABCG2 expression was 
significantly lower in NPM1 mutation(?) positive as compared to NPM1 negative AML 
samples [NPM1
mut
: 0.035 (0.01-2.02%) vs. NPM1
neg
: 1.028 (0.02-23.01%); p<0.001]. To test 
whether the association of IDH mutations with lower ABCG2 expression was independent 
from NPM1, we divided patients into three groups according to their IDH1/2 and NPM1 
mutational status (Figure 1). ABCG2 mRNA expression was the highest in the double 
negative group [IDH1/2
neg
/NPM1
neg
: 1.87 (0.02-18.05%)] comparing to the single positive 
group [IDH1/2
neg
/NPM1
mut
 and IDH1/2
mut
/NPM1
neg
: 0.62 (0.07-23.01%); p=0.013] and to the 
double positive group [IDH1/2
mut
/NPM1
mut
: 0.22 (0.01-1.61%); p<0.001). 
Interestingly, marked differences in the clinical presentation could be observed between 
IDH1 R132H and R132C mutant AML patients. R132H and R132C comparisons are noted 
with p* in Table 2, while p values reflect comparisons to IDH1/2
neg
. R132H mutant AMLs 
were more likely to have de novo origin (90%), while R132C positive AMLs were secondary 
to MDS, or therapy related in 50% of cases (p=0.08). FAB M1 was more common in R132C 
(50% vs. 0%, p=0.02). PLT at diagnosis was higher in R132H (136 vs. 45 G/L; p=0.050). 
R132H mutated AML was more likely to associate with NPM1 mutations/expression(?) than 
R132C (70 vs.14%; p=0.02). Several distinctive features were detected also between IDH2 
R140Q and R172K mutation carriers at diagnosis (comparisons are noted with p# in Table 2). 
R172K showed lower WBC (12.4 T/L vs. 22.0 T/L; p=0.028), a tendency to lower LDH level 
(411 U/L vs. 586 T/L; p=0.09) compared to R140Q carriers. R172K mutation was mutually 
exclusive with NPM1 mutations(?) (0% vs. R140Q: 47.4%; p=0.02). 
In the intermediate cytogenetic risk group consisting of 205 patients, 25 IDH1 (12.2%) and 
22 IDH2 mutations (10.7%) were identified (Supplementary Tables 1 and 2). Similarly to the 
total AML group, IDH mutations occured more often at older age and were associated with 
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higher PLT count at diagnosis. R172K was associated with lower WBC value/count(?) and 
LDH level as compared not only to the R140Q but also to the IDH1/2
neg
 subgroup. R140Q  
positive tumors preferentially showed FAB M1 subtype [R140Q: 53.3% vs. IDH1/2
neg
: 
24.8%, p=0.03]. ABCG2 mRNA expression level was lower at diagnosis in patients both with 
IDH1 and IDH2 compared to IDH1/2
neg
. Similarly to the total AML group, we noticed a 
higher ABCG2 mRNA level in the double/triple negative? IDH1/2
neg
/NPM1
neg
 group 
compared to IDH1/2
neg
/NPM1
mut 
or IDH1/2
mut
/NPM1
neg
 single positive and 
IDH1/2
mut
/NPM1
mut
 double positive subgroups (3.53 (0.15-18.05%) vs. 0.66 (0.07-2.02%); 
0.35 (0.05-1.61%), p=0.002; 0.001 respectively). HLA-DR expression was lower in IDH1 
mutant patients [IDH1
mut
: 36 (0-92%) vs. IDH1/2
neg
: 45 (0-96%), p=0.041]. CD34 was 
significantly higher in R132C vs. R132H [38 (3-89%) vs. 4 (1-68%); p=0.03]. R172K cases 
were more likely to have an intermediate risk and abnormal karyotype than R140Q samples 
(28.6% vs. 80.0 %; p=0.052). IDH1 R132H preferentially associated with NPM1 mutations(?) 
(87.5%) as compared to IDH1/2
neg 
(38.9%; p=0.009) or to R132C cases (11.1%; p=0.003). 
IDH2 R172K was mutually exclusive with NPM1 mutations(?) (0% vs. IDH1/2
neg
: 38.9%, 
R140Q: 53.3%; p=0.047, 0.022 respectively). IDH1/2
mut
 patients were less likely to carry 
FLT3 ITD mutations (IDH1/2
mut
: 19.1% vs. IDH1/2
neg
: 35.0%, p=0.048). 
 
Impact of IDH mutations on clinical outcome 
Clinical outcome was evaluated in 314 patients younger than 60 years and treated with 
curative intention in the entire AML group, including 45 IDH1/2
 mut
 and 269 IDH1/2
neg
 
patients (Supplementary Tables 3 and 4). IDH1
mut
 and IDH2
mut
 patients had similar remission 
and relapse rates compared to IDH1/2
neg
 patients. OS and DFS were not altered in IDH1
mut
 or 
IDH2
mut
 AML. On the other hand, a detailed analysis of the prognostic impact of different 
mutations revealed differences between particular IDH substitutions (Figure 2). Patients 
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harboring IDH1 R132H had a higher early death rate (R132H: 44.4% vs. IDH1/2
neg
: 12.6%; 
p=0.023), resulting in shorter OS for R132H patients compared to IDH1/2
neg
 (p=0.02) or 
R132C carriers (p=0.019). The 4-year OS was 0% in R132H, 33% in R132C, and 31% in 
IDH1/2
neg
 AML patients. In multivariate analyses (Table 3), IDH1 R132H was associated 
with shorter OS independently of age, WBC count, cytogenetic risk, and NPM1-FLT3 ITD 
status [HR (95%CI): 2.92 (1.38-6.16)], as compared to IDH1/2
neg
 AML cases. 
In the intermediate cytogenetic risk group, we evaluated 177 patients for clinical outcome, 
including 38 IDH1/2
mut
 and 139 IDH1/2
neg
 patients (Supplementary Tables 5 and 6). Similarly 
to the entire AML cohort, there were no significant differences in remission and relapse rates, 
OS and DFS between patients with or without IDH1/2 mutations. Patients harboring R132H 
had a higher early death rate (42.9% vs. 9.4%; p=0.029). R132H also showed a tendency 
toward adverse OS compared to IDH1/2
neg
 (p=0.09) and to R132C (p=0.052) groups. 
 
DISCUSSION 
IDH1 and IDH2 mutations have been described as new frequent recurrent aberrations in 
AML. In our study, we found similar mutational frequencies (IDH1: 8.5% and IDH2 7.5%) as 
reported previously (IDH1: 2.0-9.6 % and IDH2: 5.0-10.0%) in adult total AML groups (not 
excluding acute promyelocytic leukemia).(10-13, 16, 18, 20, 26) Affecting IDH1, R132C 
(3.8%) and R132H (2.7%) were the most prevalent substitutions similarly to other studies. In 
case of IDH2, R140Q occurred more frequently (5.4%) compared to R172K (2.1%). 
We confirmed that AML patients with IDH1 or IDH2 mutation share several common 
clinical characteristics like manifestation at older age (10, 12, 15, 17, 19, 26) or higher PLT 
count (10, 14, 17, 19, 21) at diagnosis. IDH mutations also occurred significantly more often 
in the cytogenetically intermediate risk AML in our cohort similarly to other reports. (10, 11, 
13-16, 18, 20, 26) Interestingly, in our cohort, IDH mutations were not associated with normal 
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karyotype. IDH mutations occurred more frequently in AML with normal karyotype in all 
reports, except for a single study.(12) Similarly to other studies, we also observed an 
association between IDH and NPM1 mutations. (10-20) As a novel common feature of IDH1 
and IDH2 mutated AML, we described that IDH mutant AML showed a reduced ABCG2 
mRNA expression. The ABCG2 multidrug transporter protein is a stem cell marker (and also 
known as a marker of cancer stem cells) and plays an important role in stem cell 
proliferation.(27) IDH mutations were shown to induce DNA and histone hypermethylation 
(2, 8) and the methylation of ABCG2 promoter may lie behind the lower transcript level of 
this transporter.(28, 29) The expression of HLA-DR, an early hematopoesis-associated 
antigen, was also lower in IDH1
mut
 compared to the IDH1/2
neg
 AML subgroup within the 
intermediate karyotype risk group, similarly to a previous report by Chou et al.(13) Other 
reports discovered a specific association between NPM1 and IDH mutations by clustering 
samples according to their methylation profile similarity. (30, 31) 
Despite the strikingly similar clinical features of IDH1
mut
 and IDH2
mut
 AML, recently a 
few studies demonstrated differences between IDH2 mutations occuring at sites R140 and 
R172 in AML cases.(14, 16) Similarly to their reports, we confirmed that R172K mutation 
showed lower WBC, lower LDH, higher likelihood for having intermediate risk abnormal 
karyotype compared to R140Q, as well as the lack of co-occurrence with mutant NPM1. As a 
novel finding, we observed distinct clinical characteristics of IDH1 mutations affecting the 
same codon, R132H and R132C. There was a tendency that R132H mutation associated more 
frequently with de novo AML etiology compared to R132C mutation (90% vs. 50%, p=0.08). 
In IDH1 R132H positive AML, acute myeloblastic leukemia without maturation (FAB M1) 
morphology was less frequent (p=0.02); PLT count at diagnosis was higher (p=0.05) and 
NPM1 co-occured more frequently (p=0.02). 
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Contrary to the similar clinical characteristics of IDH1 and IDH2 mutations, data on the 
prognostic impact of different IDH mutations were reported to be more controversial. 
Grouping together the mutations with different prognostic impact may be one reason of the 
inconsistent reports. Several studies have found no prognostic impact of IDH2 mutations,(17, 
19, 21, 26) while others suggested that R140 confers good and R172 adverse prognosis.(3, 11, 
14, 16, 17) In our patient cohort, no prognostic difference was detected with respect to the 
IDH2 subgroup, possibly due to the low number of cases. IDH1 was generally considered as a 
weak prognostic factor exerting its adverse effect only in special AML subgroups (like FLT3 
ITD negative,(15) NPM1 negative (18, 20) or NPM1 positive (11)). In our study, IDH1 
R132H was an independent adverse prognostic factor affecting early death rate and OS, while 
R132C did not differ from IDH
neg
 AML samples. 
In the central nervous system (CNS), the vast majority (80-90%) of IDH1 mutations is 
R132H, while R132C is more frequent in the haematopoietic clonal disorders. Scientific  
literature data reveals that R132H occurs less frequently in IDH1
mut
 MPN (0%, p<0.0001) and 
in IDH1
mut
 MDS (p=0.085) compared to IDH1
mut
 AML (Table 4). Differences in the observed 
frequencies of R132H and R132C in CNS tumors, AML, and MPN suggest possible 
functional variations among IDH1 codon R132 mutants. Although the ability to produce 2HG 
was similar in both R132 variants, kinetic analyses showed that the R132C substitution 
impairs the oxidative decarboxylation of isocitrate to αKG more severely as compared to 
R132H.(32-34) 
In summary, we identified IDH1 and IDH2 mutations in 16% of AML. Although we 
confirmed the previously reported common clinical characteristics (older age at presentation, 
higher platelet count, association with intermediate risk karyotype and nucleophosmin 
mutation), we observed distinct clinical features among IDH1 R132C and R132H or IDH2 
R140 and R172 mutations. This is the first report to draw attention that different mutations 
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affecting the same codon of IDH1 might associate with distinct features and prognostic 
impact. Further studies with larger numbers of AML patients could extend our results and 
might reveal other unexpected genotype-phenotype correlations. 
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FIGURES 
Figure 1. Boxplot expression (median and quartiles) of ABCG2 expression in AML according 
to IDH1/2 mutation status alone (Panel A), according to NPM1 mutation status alone (Panel 
B) and IDH1/2 and NPM1 mutation status combined (Panel C).  
 
Figure 2. 
 
Panel A. Overall survival analysis of AML patients according to the different IDH1 and 
IDH2 mutations. R132H, R132C, R140Q, R172K vs. IDH1/2
neg
 p=0.02, 0.742, 0.357, 0.197 
respectively; R132C vs. R132H p=0.019; R140Q vs. R172K p=0.455. 
Panel B. Disease free survival analysis of AML patients according to the different IDH1 
and IDH2 mutations. R132H, R132C, R140Q, R172K vs. IDH1/2
neg
  p=0.091, 0.892, 0.545, 
0.253 respectively; R132C vs. R132H p=0.122; R140Q vs. R172K p=0.399 
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Table 1. Pre-treatment, clinical and molecular characteristics according to IDH1 and IDH2 mutation status. Comparisons are presented between 
IDH1 and IDH2 double negative and IDH1 or IDH2 positive patients in the entire AML group. 
Characteristics in the entire AML 
cohort 
IDH 1/2 negative 
n=316 (84.1%) 
IDH1 mutant 
n=32 (8.5%) 
P IDH2 mutant 
n=28 (7.4%) 
P 
Number/ 
median 
%/ 
range 
Number/ 
median 
%/ 
range 
 Number/ 
median 
%/ 
range 
 
Age median, (range) (n=376) 49.0 (16-86) 54.5 (30-93) 0.013 56.5 (31-77) 0.009 
Sex (male/ female; %) 156/160 (49.4%/50.6%) 11/21 (34.4/65.6%) 0.137 13/15 (46.4/53.6%) 0.845 
Type of AML (n, %) 
De novo 190/314 (60.5%) 22/32 (68.8%) 0.447 20/26 (76.9%) 0.140 
MDS 101/314 (32.2%) 6/32 (18.8%) 0.159 6/26 (23.1%) 0.388 
t-AML 23/314 (7.3%) 4/32 (12.4%) 0.296 0/26 (0.0%) 0.238 
FAB (n, %) 
M0 11/282 (3.9%) 0/29 (0.0%) 0.608 0/25 (0.0%) 0.609 
M1 66/282 (23.4%) 8/29 (27.6%) 0.648 10/25 (40.0%) 0.088 
M2 37/282 (13.1%) 6/29 (20.7%) 0.261 0/25 (0.0%) 0.055 
M3 31/282 (10.9%) 0/29 (0.0%) 0.094 2/25 (8.0%) 1 
M4 78/282 (27.7%) 11/29 (37.9%) 0.281 9/25 (36.0%) 0.364 
M5 53/282 (18.8%) 4/29 (13.8%) 0.621 4/25 (16.0%) 1 
M6 3/282 (1.1%) 0/29 (0.0%) 1 0/25 (0.0%) 1 
M7 3/282 (1.1%) 0/29 (0.0%) 1 0/25 (0.0%) 1 
Laboratory data, median (range) 
WBC, T/L (n=347) 10.5 (0.3-368) 10.7 (0.09-301) 0.832 6.91 (0.8-300) 0.294 
PLT, G/L (n=278) 39 (5-684) 75 (10-326) 0.039 72 (5-215) 0.005 
LDH, U/L (n=347) 734 (136-15418) 730 (260-4040) 0.710 571 (217-4500) 0.139 
ABCG2, % (n=80) 1.35 (0.02-18.05) 0.52 (0.01-23.01) 0.062 0.51 (0.05-3.24) 0.012 
HLA-DR, % (n=235) 45 (0-96) 32 (0-92) 0.241 23 (0-89) 0.182 
CD13, % (n=229) 54 (0-99) 56 (7-91) 0.943 55 (14-92) 0.668 
CD33, % (n=238) 68 (1-98) 68.5 (8-96) 0.414 60 (17-94) 0.236 
CD34, % (n=238) 22 (0-95) 13 (0-89) 0.923 10 (0-88) 0.735 
CD14, % (n=188) 2 (0-95) 1.5 (0-20) 0.310 2 (0-25) 0.861 
CD7, % (n=231) 12 (0-93) 8.5 (0-60) 0.733 10 (4-68) 0.514 
Cytogenetics (n, %) 
Favourable 61/300 (20.3%) 2/31 (6.5%) 0.089 2/27 (7.4%) 0.128 
Intermediate 158/300 (52.7%) 25/31 (80.6%) 0.004 22/27 (81.5%) 0.004 
Adverse 81/300 (27.0%) 4/31 (12.9%) 0.128 3/27 (11.1%) 0.105 
Mutations (n, %) 
FLT3 ITD + 70/315 (22.2%) 6/32 (18.8%) 0.823 4/28 (14.3%) 0.472 
NPM1 + 73/315 (23.2%) 13/31 (42.0%) 0.029 9/28 (33.3%) 0.244 
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Table 2. Pre-treatment, clinical and molecular characteristics of the most common IDH1 R132C, R132H and IDH2 R140Q, R172K mutations in the 
entire AML group. Comparisons are presented between IDH1 and IDH2 double negative (shown in Table 1.) and the individual mutations (p values). 
Comparisons between IDH1 R132C and R132H are presented with p* and comparisons between IDH2 R140Q and R172K are presented with p# 
values. 
Characteristics in the 
entire AML cohort 
R132C+ 
n=14 (3.7%) 
P R132H+ 
n=10 (2.7%) 
P P* R140Q+ 
n=20 (5.3%) 
P R172K+ 
n=8 (2.1%) 
P P# 
Numb
er/ 
media
n 
%/ 
range 
Number/ 
median 
%/ 
range 
Number/ 
median 
%/ 
range 
Number/ 
median 
%/ 
range 
Age median,( range) 57 (33-93) 0.024 52 (30-66) 0.561 0.285 56.5 (40-77) 0.009 56.5 (31-66) 0.415 0.746 
Sex (male/ 
female; %) 
5/9 (35.7/64.3%
) 
0.416 3/7 (30.0/ 
70.0%) 
0.338 0.56 11/9 (55.0/ 
45.0%) 
0.652 2/6 (25.0/ 
75.0%) 
0.284 0.16 
Type of AML(n, %)               
De novo 7/14 (50.0%) 0.578 9/10 (90.0%) 0.095 0.08 15/18 (83.3%) 0.078 5/8 (62.5%) 1 0.33 
MDS 4/14 (28.6%) 1 1/10 (10.0%) 0.179 0.36 3/18 (16.7%) 0.201 3/8 (37.5%) 0.716 1 
t-AML 3/14 (21.4%) 0.089 0/10 (0.0%) 1 0.24 0/18 (0.0%) 0.624 0/8 (0.0%) 1 1 
FAB (n, %)               
M0 0/12 (0.0%) 1 0/9 (0.0%) 1 - 0/20 (0.0%) 1 0/5 (0.0%) 1 - 
M1 6/12 (50.0%) 0.078 0/9 (0.0%) 0.217 0.02 9/20 (45.0%) 0.056 1/5 (20.0%) 1 0.61 
M2 1/12 (8.3%) 1 3/9 (3.3%) 0.112 0.27 0/20 (0.0%) 0.149 0/5 (0.0%) 1 - 
M3 0/12 (0.0%) 0.623 0/9 (0.0%) 0.604 - 2/20 (10.0%) 1 0/5 (0.0%) 1 1 
M4 4/12 (33.3%) 0.744 4/9 (44.4%) 0.275 0.67 5/20 (25.0%) 1 4/5 (80.0%) 0.025 0.04 
M5 1/12 (8.3%) 0.702 2/9 (22.2%) 0.680 0.55 4/20 (20.0%) 1 0/5 (0.0%) 0.588 0.55 
M6 0/12 (0.0%) 1 0/9 (0.0%) 1 - 0/20 (0.0%) 1 0/5 (0.0%) 1 - 
M7 0/12 (0.0%) 1 0/9 (0.0%) 1 - 0/20 (0.0%) 1 0/5 (0.0%) 1 - 
Laboratory data, median( range) 
WBC, T/L 8.4 (1-301) 0.685 14.5 (0.09-100) 0.946 0.794 12.4 (0.8-300) 0.846 22.0 (1.2-25.1) 0.019 0.028 
PLT, G/L 45 (10-154) 0.982 136 (25-326) 0.017 0.050 68.5 (5-215) 0.015 79 (12-140) 0.132 0.929 
LDH, U/L 700 (260-4040) 0.349 1204 (484-2079) 0.438 0.164 586 (304-
4500) 
0.571 411 (217-
1398) 
0.043 0.092 
ABCG2, % 0.52 (0.01-1.94) 0.045 0.79 (0.22-23.01) 0.738 0.513 0.38 (0.05-
1.61) 
0.008 0.69 (0.22-
3.24) 
0.481 0.304 
HLA-DR, % 24 (9-92) 0.289 26.5 (0-75) 0.225 0.867 21.5 (0-89) 0.139 44.5 (22-67) 0.976 0.606 
CD13, % 71 (9-91) 0.569 51.5 (7-82) 0.484 0.463 55 (14-92) 0.564 47.5 (20-75) 0.821 0.606 
CD33, % 54 (18-89) 0.414 69 (8-87) 0.469 1 61 (17-94) 0.391 45.5 (31-60) 0.295 0.513 
CD34, % 38 (3-89) 0.151 3.5 (1-68) 0.340 0.054 1 (0-88) 0.700 65 (51-79) 0.070 0.513 
CD14, % 1 (1-4) 0.433 2 (0-20) 0.726 0.710 2 (1-25) 0.645 4 (0-8) 0.646 0.667 
CD7, % 8 (3-56) 0.784 15 (3-50) 0.920 0.779 10 (4-68) 0.634 12.5 (4-21) 0.602 0.909 
Cytogenetics (n, %)               
Favourable 0/13 (0.0%) 0.080 2/10 (20.0%) 1 0.18 2/19 (10.5%) 0.386 0/8 (0.0%) 0.364 1 
Intermediate 9/13 (69.2%) 0.271 8/10 (80.0%) 0.113 0.66 15/19 (79.0%) 0.583 7/8 (87.5%) 0.072 1 
Adverse 4/13 (30.8%) 0.755 0/10 (0.0%) 0.069 0.10 2/19 (10.5%) 0.175 1/8 (12.5%) 0.686 1 
Mutations (n, %)               
FLT3 ITD + 2/14 (14.3%) 0.742 2/10 (20.0%) 1 0.82 4/20 (20.0%) 1 0/8 (0.0%) 0.209 0.240 
NPM1 + 2/14 (14.3%) 0.744 7/10 (70.0%) 0.003 0.02 9/19 (47.4%) 0.026 0/8 (0.0%) 0.206 0.020 
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Table 3. Multivariate analysis for overall and disease-free survival in all AML patients. IDH1 R132H mutation is an independent adverse prognostic 
factor of age, karyotype (in the entire AML cohort), and NPM1-FLT3 risk. 
Discovery  cohort Entire AML Intermediate AML 
 OS DFS OS DFS 
 HR 95%Cl p HR 95%Cl p HR 95%Cl p HR 95%Cl p 
Age 1.02 1.00-1.03 0.002 1.02 1.00-1.03 0.002 1.02 1.00-1.04 0.023 1.02 1.00-1.04 0.046 
Karyotype 2.09 1.68-2.62 0.000 2.04 1.64-2.54 0.000       
NPM1-FLT3 risk* 0.63 0.39-1.04 0.069 0.60 0.37-0.97 0.041 0.511 0.29-0.88 0.016 0.49 0.28-0.84 0.010 
R132H mutation** 2.92 1.44-5.89 0.003 2.28 1.13-4.58 0.021 2.33 1.05-5.15 0.037 1.83 0.83-4.04 0.132 
*NPM1-FLT3 risk: low risk (NPM1 positive and FLT3 negative) vs. high risk group (NPM1 negative and FLT3 negative, NPM1 positive and FLT3 
positive, NPM1 negative and FLT3 positive combined). ** R132H positive patients vs. IDH1/2 negative patients. 
 
 
Remarks and abbreviations for Tables 1-3: 
Significant p values are shown in bold. P values present comparisons between IDH mutation positive and IDH1/2 double negative (IDH1/2
neg
) 
patients. P* values present comparisons between IDH1 R132C and R132H, p# values present comparisons between IDH2 R140Q and R172K 
mutation positive patients. 
Abbreviations: ABCG2: ABCG2: ATP-binding cassette sub-family G member 2 expression at diagnosis; AML: acute myeloid leukemia; FAB: 
morphology according to French-American British classification; FLT3 ITD+: fms-like tyrosine kinase internal tandem duplication positive; IDH: 
isocitrate dehydrogenase; LDH: lactate dehydrogenase at diagnosis; MDS: myelodysplastic syndrome; MDS-AML: AML evolving from a primary 
documented myelodysplastic syndrome; MPN: myeloproliferative diseases; N.A. not applicable; NPM1+: nucleophosmin 1 positive; PLT: platelet 
count at diagnosis; t-AML: therapy-related myeloid neoplasm; WBC: white blood cell count at diagnosis; OS:overall survival; DFS: disease free 
survival; HR:hazard ratio; 95%Cl: 95% confidence interval. 
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Table 4. Recent studies on the frequency of IDH1 R132H and R132C mutations in MPN, MDS and AML. 
Author Disease Clinical correlates 
Number 
of 
patients 
in the 
study [n] 
Number 
of IDH1 
R132 
mutants 
in the 
study [n] 
Number 
of 
R132H 
mutants 
in the 
study [n] 
R132H 
vs IDH1 
R132 
total 
[%] 
Number 
of 
R132HC 
mutants 
in the 
study [n] 
R132C 
vs IDH1 
R132 
total 
[%] 
Tefferi et al.* (35) 
 
MPN 
includes post MPN AML 1473 18 0 0,0% 7 38,9% 
Green et al. (36) MPN  16 3 0 0,0% 3 100,0% 
Pardanani et al.* (37) MPN includes post MPN AML 200 5 0 0,0% 4 80,0% 
  SUMMARY  27 0 0% 14 51,9% 
Rocquain et al. (38) MDS  65 2 0 0,0% 2 100,0% 
Kosmider et al. (39) MDS  100 2 0 0,0% 0 0,0% 
Thol et al.** (22) MDS  193 7 1 14,3% 6 85,7% 
Lin et al. (26) MDS  82 2 1 50,0% 0 0,0% 
  SUMMARY  13 2 15,4% 8 61,5% 
Ho et al. (43) AML children 257 0 0 na 0 na 
Kosmider et al. (39) AML secondary 41 2 0 0,0% 2 100,0% 
Zou et al. (40) AML  68 5 0 0,0% 2 40,0% 
Schnittger et al. (41) AML  1414 93 6 6,5% 51 54,8% 
Chou et al. (13) AML adult AML 493 27 7 25,9% 10 37,0% 
Chotirat et al. (12) AML newly diagnosed AML 230 20 8 40,0% 6 30,0% 
Boissel et al. (11) AML de novo, adult AML 520 50 22 44,0% 21 42,0% 
Paschka et al. (19) AML  805 61 28 45,9% 20 32,8% 
Marcucci et al. (17) AML de novo, CN-AML 358 49 23 46,9% 15 30,6% 
Thol et al.** (22) AML secondary AML (arising from MDS) 53 4 2 50,0% 1 25,0% 
Green et al. (42) AML  1333 107 54 50,5% 35 32,7% 
Abbas et al. (10) AML newly diagnosed AML 893 55 31 56,4% 15 27,3% 
Ho et al. (43) AML young adult 274 12 8 66,7% 1 8,3% 
Rocquain et al. (38) AML including 46 primary cases and 18 arising from MDS 64 3 2 66,7% 1 33,3% 
Wagner et al.** (23) AML CN-AML 275 29 20 69,0% 5 17,2% 
Lin et al. (26) AML  198 4 3 75,0% 0 0,0% 
  SUMMARY  521 214 41,1% 185 35,5% 
 Possible overlapping in patients cohorts between *Tefferi and Pardanani, **Thol and Wagner 
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Supplementary Table 1. Pre-treatment, clinical and molecular characteristics according to IDH1 and IDH2 mutation status in the intermediate 
cytogenetic risk AML group. Comparisons are presented between IDH1 and IDH2 double negative and IDH1 or IDH2 positive patients. 
 
Characteristics in the intermedier 
cytogenetic risk AML group 
IDH 1/2 negative 
(n=158; 77.0=%) 
IDH1 mutant 
(n=25, 12.3%) 
P IDH2 mutant 
(n=22, 10.7%) 
 
P 
Number/ 
median 
%/ 
range 
Number/ 
median 
%/ 
range 
 Number/ 
median 
%/ 
range 
 
Age median,( range)(n=205) 48 (18-86) 53 (30-72) 0.041 54 (31-66) 0.052 
Sex (male/ female; %) 75/83 (47.5%/52.5%) 9/16 (36.0%/64.0%) 0.388 9/13 (40.9%/59.1%) 0.651 
Type of AML(n, %)         
De novo 117/158 (74.0%) 19/25 (76.0%) 1 17/20 (85.0%) 0.411 
MDS 26/158 (16.5%) 3/25 (12.0%) 0.771 3/20 (15.0%) 1 
t-AML 15/158 (9.5%) 3/25 (12.0%) 0.717 0/20 (0.0%) 0.225 
FAB (n, %)         
M0 5/145 (3.5%) 0/23 (0.0%) 1 0/20 0 (0.0%) 1 
M1 36/145 (24.8%) 6/23 (26.1%) 1 9/20 9 (45.0%) 0.066 
M2 16/145 (11.0%) 4/23 (17.4%) 0.484 0/20 0 (0.0%) 0.223 
M3 0/145 (0.0%) 0/23 (0.0%) na 0/20 0 (0.0%) na 
M4 50/145 (34.5%) 9/23 (39.1%) 0.647 8/20 8 (40.0%) 0.626 
M5 37/145 (25.5%) 4/23 (17.4%) 0.601 3/20 3 (15.0%) 0.409 
M6 1/145 (0.7%) 0/23 (0.0%) 1 0/20 0 (0.0%) 1 
M7 0/145 (0.0%) 0/23 (0.0%) na 0/20 0 (0.0%) na 
Laboratory data, median (range)         
WBC, T/L (n=194) 18.8 (0.3-368) 14.5 (0.09-180) 0.356 8.61 (0.8-300) 0.072 
PLT, G/L (n=149) 44.5 (5-365) 81 (12-326) 0.118 73 (5-215) 0.029 
LDH, U/L (n=190) 917 (187-7630) 753 (260-2079) 0.223 592 (217-4500) 0.072 
ABCG2, % (n=48) 1.37 (0.07-18.05) 0.37 (0.11-3.13) 0.041 0.35 (0.05-1.61) 0.019 
HLA-DR, % (n=134) 45 (0-96) 36 (0-92) 0.041 22 (0-89) 0.323 
CD13, % (n=134) 54 (0-99) 35 (7-91) 0.471 48 (14-92) 0.519 
CD33, % (n=136) 70 (1-98) 73 (8-96) 0.150 60.5 (17-94) 0.071 
CD34, % (n=136) 22 (0-95) 6 (0-89) 0.941 5.5 (0-88) 0.204 
CD14, % (n=112) 2 (0-95) 1.5 (0-20) 0.172 2 (0-25) 0.695 
CD7, % (n=129) 12 (0-93) 21 (0-56) 1 9 (4-22) 0.914 
Mutations (n, %)         
FLT3 ITD + 55/157 (35.0%) 5/25 (20.0%) 0.172 4/22 (18.2%) 0.148 
NPM1 + 61/157 (38.9%) 12/24 (50.0%) 0.372 8/22 (36.4%) 1 
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Supplementary Table 2. Pre-treatment, clinical and molecular characteristics of the most common IDH1 R132C, R132H and IDH2 R140Q, R172K 
mutations in the intermediate cytogenetic risk AML group. Comparisons are presented between IDH1 and IDH2 double negative (shown in Table 1.) 
and the individual mutations (p values). Comparisons between IDH1 R132C and R132H are presented with p* and comparisons between IDH2 
R140Q and R172K are presented with p# values. 
Characteristics R132C 
(n=9, 4.4%) 
P 
 
R132H 
(n=8, 3.9%) 
P P* R140Q 
(n=15, 7.3%) 
P 
 
R172K 
(n=7, 3.4%) 
P P# 
Number/ 
median 
%/ 
range 
Number/ 
median 
%/ 
range 
Number/ 
median 
%/ 
range 
Number/ 
median 
%/ 
range 
Age median 
(,range) 
51 (33-72) 0.362 54 (30-66) 0.276 0.815 54 (40-64) 0.036 54 (31-66) 0.648 0.731 
Sex (male/ 
 female; %) 
3/6 (33.3%/ 
66.7%) 
0.505 3/5 (37.5%/ 
62.5%) 
0.724 1 7/8 (46.7%/ 
53.3%) 
1 2/5 (28.6%/ 
71.4%) 
0.0451 0.648 
Type of AML(n, %) 
De novo 6/9 (66.7%) 0.699 7/8 (87.5%) 0.681 0.577 12/13 (92.3%) 0.191 5/7 (71.4%) 1 0.270 
MDS 1/9 (11.1%) 1 1/8 (12.5%) 1 1 1/13 (7.7%) 0.695 2/7 (28.6%) 0.339 0.270 
t-AML 2/9 (22.2) 0.229 0/8 (0.0%) 1 0.471 0/13 (0.0%) 0.608 0/7 (0.0%) 1 na 
FAB (n, %)               
M0 0/8 (0.0%) 1 0/7 (0.0%) 1 na 0/15 (0.0%) 1 0/5 (0.0%) 1 na 
M1 4/8 (50.0%) 0.207 0/7 (0.0%) 0.198 0.077 8/15 (53.3%) 0.030 1/5 (20.0%) 1 0.319 
M2 0/8 (0.0%) 1 2/7 (28.6%) 0.194 0.200 0/15 (0.0%) 0.367 0/5 (0.0%) 1 na 
M3 0/8 (0.0%) na 0/7 (0.0%) na na 0/15 (0.0%) na 0/5 (0.0%) na na 
M4 3/8 (37.5%) 0.169 3/7 (42.7%) 0.695 1 4/15 (26.7%) 0.775 4/5 (80.0%) 0.057 0.109 
M5 1/8 (12.5%) 0.680 2/7 (28.6%) 1 0.569 3/15 (20.0%) 0.763 0/5 (0.0%) 0.334 0.539 
M6 0/8 (0.0%) 1 0/7 (0.0%) 1 na 0/15 (0.0%) 1 0/5 (0.0%) 1 na 
M7 0/8 (0.0%) na 0/7 (0.0%) na na 0/15 (0.0%) na 0/5 (0.0%) na na 
Laboratory data, median (range) 
WBC, T/L  6.335 (1-180) 0.103 18.1 (0.09-100) 0.687 0.442 14.7 (0.8-300) 0.702 2.4 (1.2-25.1) 0.006 0.047 
PLT, G/L  45 (12-118) 0.581 136 (25-326) 0.032 0.082 71 (5-215) 0.038 76 (12-140) 0.342 0.765 
LDH, U/L  711.5 (260-1693) 0.298 1067 (484-2079) 0.944 0.574 680 (320-4500) 0.399 452 (217-1398) 0.031 0.112 
ABCG2, % 0.38 (0.11-1.94) 0.092 0.57 (0.22-1.47) 0.253 1 0.34 (0.05-1.61) 0.041 0.65 (0.22-0.74) 0.192 0.905 
HLA-DR, % 28 (9-92) 0.083 36 (14-75) 0.042 0.931 19 (0-89) 0.287 44.5 (22-67) 0.918 0.889 
CD13, %  35 (9-91) 0.706 49 (7-82) 0.332 0.931 48 (14-92) 0.384 47.5 (20-75) 0.781 0.533 
CD33, %  54 (18-89) 0.223 65 (8-87) 0.294 1 63.5 (17-94) 0.170 45.5 (31-60) 0.188 0.582 
CD34, %  38 (3-89) 0.316 4 (1-68) 0.243 0.030 1 (0-88) 0.566 65 (51-79) 0.062 0.727 
CD14, % 1 (1-2) 0.380 2 (0-20) 0.513 1 2 (1-25) 0.946 4 (0-8) 0.548 0.857 
CD7, %  23 (6-56) 0.483 21 (3-50) 0.740 0.429 9 (4-22) 0.940 12.5 (4-21) 0.704 0.711 
Mutations (n, %) 
FLT3 ITD + 1/9 (11.1%) 0.275 2/8 (25.0%) 0.716 0.576 4/15 (26.7%) 0.583 0/7 (0.0%) 0.096 0.263 
NPM1 + 1/9 (11.1%) 0.156 7/8 (87.5%) 0.009 0.003 8/15 (53.3%) 0.285 0/7 (0.0%) 0.047 0.022 
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Supplementary Table 3. Treatment outcome according to IDH1 and IDH2 mutations in the entire AML group. Comparisons are presented between 
IDH1 and IDH2 double negative and IDH1 or IDH2 positive patients. 
Characteristics in the entire 
AML 
IDH 1/2 negative IDH1 mutant P IDH2 mutant P 
n % n % n % 
Complete remission 184/269 (68.4%) 17/24 (70.8%) 1 18/21 (85.7%) 0.138 
Early death 34/269 (12.6%) 5/24 (20.8%) 0.361 1/21 (4.8%) 0.487 
Resistant disease 51/269 (19.0%) 2/24 (8.3%) 0.272 2/21 (9.5%) 0.387 
Relapse 98/184 (53.3%) 9/17 (52.9%) 1 11/18 (61.1%) 0.624 
Alive 81/269 (30.1%) 5/24 (20.8%) 0.483 9/21 (42.9%) 0.229 
 
Supplementary Table 4. Treatment outcome of the most common IDH1 R132C, R132H and IDH2 R140Q, R172K mutations in the total AML 
group. Comparisons are presented between IDH1 and IDH2 double negative (shown in Table 3.) and the individual mutations (p values). 
Comparisons between IDH1 R132C and R132H are presented with p* and comparisons between IDH2 R140Q and R172K are presented with p# 
values. 
Characteristics in 
the entire AML 
R132C P R132H P P* R140Q P R172K P P# 
N % n % n % n % 
Complete remission 7/9 (77.8%) 0.725 5/9 (55.6%) 0.474 0.619 13/16 (81.3%) 0.406 5/5 (100.0%) 0.329 0.549 
Early death 1/9 (11.1%) 1 4/9 (44.4%) 0.023 0.294 1/16 (6.3%) 0.702 0/5 (0.0%) 1 1 
Resistant disease 1/9 (11.1%) 1 0/9 (0.0%) 0.373 1 2/16 (12.5%) 0.745 0/5 (0.0%) 0.588 1 
Relapse 4/7 (57.1%) 1 4/5 (80.0%) 0.376 0.576 8/13 (61.5%) 0.775 3/5 (60.0%) 1 1 
Alive 2/9 (22.2%) 1 0/9 (0.0%) 0.063 0.471 6/16 (37.5%) 0.579 3/5 (60.0%) 0.169 0.611 
 
Supplementary Table 5. Treatment outcome according to IDH1 and IDH2 mutations in the intermedier cytogenetic risk AML group. Comparisons 
are presented between IDH1 and IDH2 double negative and IDH1 or IDH2 positive patients. 
 
Characteristics in intermedier 
cytogenetic risk AML 
IDH 1/2 negative IDH1 mutant P IDH2 mutant P 
n % n % n % 
Complete remission 100/139 (71.9%) 17/25 (68.0%) 0.810 15/18 (83.3%) 0.403 
Early death 13/139 (9.4%) 4/25 (16.0%) 0.298 1/18 (5.6%) 1 
Resistant disease 26/139 (18.7%) 4/25 (16.0%) 1 2/18 (11.1%) 0.743 
Relapse 58/100 (58.0%) 10/17 (58.8%) 1 8/15 (53.3%) 0.784 
Alive 39/139 (28.1%) 5/25 (20.0%) 0.472 7/18 (38.9%) 0.410 
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Supplementary Table 6. Treatment outcome of the most common IDH1 R132C, R132H and IDH2 R140Q, R172K mutations in the intermedier 
cytogenetic risk AML group. Comparisons are presented between IDH1 and IDH2 double negative (shown in Table 3.) and the individual mutations 
(p values). Comparisons between IDH1 R132C and R132H are presented with p* and comparisons between IDH2 R140Q and R172K are presented 
with p# values. 
 
Characteristics in 
intermedier 
cytogenetic risk 
AML 
R132C P R132H P P* R140Q P* R172K P* P* 
N % n % n % n % 
Complete remission 5/7 (71.4%) 1 4/7 (57.1%) 0.411 1 10/13 (76.9%) 1 5/5 (100.0%) 0.324 0.522 
Early death 1/7 (14.3%) 0.514 3/7 (42.9%) 0.029 0.559 1/13 (7.7%) 1 0/5 (0.0%) 1 1 
Resistant disease 1/7 (14.3%) 1 0/7 (0.0%) 0.353 1 2/13 (15.4%) 1 0/5 (0.0%) 0.585 1 
Relapse 2/5 (40.0%) 0.649 4/4 (57.1%) 0.146 0.167 5/10 (50.0%) 0.742 3/5 (60.0%) 1 1 
Alive 2/7 (28.6%) 1 0/7 (0.0%) 0.189 0.462 4/13 (30.8%) 1 3/5 (60.0%) 0.148 0.326 
 
Remarks and abbreviations for Supplementary Tables 1-6: 
Significant p values are shown in bold. P values present comparisons between IDH mutation positive and IDH1/2 double negative (wild type, WT) 
patients. P* values present comparisons between IDH1 R132C and R132H, p# values present comparisons between IDH2 R140Q and R172K 
mutation positive patients. 
Abbreviations: ABCG2: ABCG2: ATP-binding cassette sub-family G member 2 expression at diagnosis; AML: acute myeloid leukemia; FAB: 
morphology according to French-American British classification; FLT3 ITD+: fms-like tyrosine kinase internal tandem duplication positive; IDH: 
isocitrate dehydrogenase; LDH: lactate dehydrogenase at diagnosis; MDS-AML: AML evolving from a primary documented myelodysplastic 
syndrome; N.A. not applicable; NPM1+: nucleophosmin 1 positive; PLT: platelet count at diagnosis; t-AML: therapy-related myeloid neoplasm; 
WBC: white blood cell count at diagnosis. 
 
 
